GELBMAN RONALD G 4

4 · HAEMONETICS CORP · Filed Nov 13, 2019

Form 4

Period: 2019-11-11

Director

Transactions

Exercise/Conversion
Common Stock
2019-11-11$45.45/sh+6,573$298,743→ 54,957 total
Exercise/Conversion
Common Stock
2019-11-11$35.50/sh+10,353$367,552→ 65,310 total
Sale
Common Stock
2019-11-11$118.26/sh−16,926$2,001,669→ 48,384 total
Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2019-11-11−10,353→ 0 total
Exercise: $35.50From: 2015-07-23Exp: 2021-07-23→ Common Stock (10,353 underlying)
Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2019-11-11−6,573→ 0 total
Exercise: $45.45From: 2014-07-24Exp: 2020-07-24→ Common Stock (6,573 underlying)

Footnotes (3)

[F1]This number includes unvested restricted stock units previously reported.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.97 to $118.83, inclusive. the reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
[F3]Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

Documents

1 file